These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20222030)

  • 1. Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro.
    Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
    J Clin Apher; 2010; 25(2):54-62. PubMed ID: 20222030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis.
    Pütz G; Eckes J; Schmah O; Winkler K; Wieland H
    Ther Apher Dial; 2008 Feb; 12(1):2-12. PubMed ID: 18257806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
    Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
    BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.
    Ngoune R; Contini C; Hoffmann MM; von Elverfeldt D; Winkler K; Putz G
    Curr Drug Deliv; 2018; 15(9):1261-1270. PubMed ID: 29779479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy.
    Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
    Med Hypotheses; 2009 Apr; 72(4):393-7. PubMed ID: 19147297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
    Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
    Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
    Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
    Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of pegylated liposomal doxorubicin in ovarian cancer.
    Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
    Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.